Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head and Neck Squamous Cell Cancer.

Trial Profile

Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head and Neck Squamous Cell Cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2013 Planned end date changed from 1 Jun 2016 to 1 Jun 2021 as reported by ClinicalTrials.gov.
    • 30 Aug 2011 Additional lead trial centre and investigator identified as reported by Clinical Trials Registry - India; CTRI2010-091-001230).
    • 30 Aug 2011 New source identified and integrated (Clinical Trials Registry - India; CTRI2010-091-001230).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top